DexCom Inc (DXCM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $31.08B
Last updated: Nov 17, 2026 at 11:05 AM ET
DexCom Inc (DXCM) Financials: Revenue, Profit and Cash Flow
DexCom reported revenue of $4.66B for the fiscal year ended Dec 31, 2025, up 15.6% from the year before. That year, net income was $836.30M with a net margin of 17.9%, operating cash flow was $1.44B and free cash flow was $1.08B. The quarter ended Sep 30, 2026 had revenue of $1.34B and net income of $275.10M.
Revenue and Margins
The operating margin was 19.6% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $573.30M, a compound annual rate of 26.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.66B | +15.6% | 60.1% | 19.6% | 17.9% |
| Dec 2024 | $4.03B | +11.3% | 60.5% | 14.9% | 14.3% |
| Dec 2023 | $3.62B | +24.5% | 63.2% | 16.5% | 14.9% |
| Dec 2022 | $2.91B | +18.8% | 64.7% | 13.4% | 11.7% |
| Dec 2021 | $2.45B | +27.1% | 68.6% | 10.9% | 8.9% |
| Dec 2020 | $1.93B | +30.5% | 66.4% | 15.5% | 28.5% |
| Dec 2019 | $1.48B | +43.1% | 63.1% | 9.6% | 6.8% |
| Dec 2018 | $1.03B | +43.6% | 64.4% | -18.1% | -12.3% |
| Dec 2017 | $718.50M | +25.3% | 68.5% | -5.9% | -7.0% |
| Dec 2016 | $573.30M | N/A | 66.0% | -11.1% | -11.4% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 45.1% from the year before. In the quarter ended Sep 2026, net income fell 3.1% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.66B | $4.03B | $3.62B | $2.91B | $2.45B | $1.93B | $1.48B | $1.03B | $718.50M | $573.30M |
| Cost of revenue | $1.86B | $1.59B | $1.33B | $1.03B | $768.00M | $646.60M | $544.50M | $367.70M | $226.40M | $194.90M |
| Gross profit | $2.80B | $2.44B | $2.29B | $1.88B | $1.68B | $1.28B | $931.50M | $663.90M | $492.10M | $378.40M |
| Research and development | $599.10M | $552.40M | $505.80M | $484.20M | $604.20M | $359.90M | $273.50M | $417.40M | $185.40M | $156.10M |
| Operating income | $911.80M | $600.00M | $597.70M | $391.20M | $265.80M | $299.50M | $142.30M | -$186.30M | -$42.50M | -$63.90M |
| Net income | $836.30M | $576.20M | $541.50M | $341.20M | $216.90M | $549.70M | $101.10M | -$127.10M | -$50.20M | -$65.60M |
| EBITDA | $1.34B | $926.70M | $896.40M | $546.70M | $358.80M | $382.70M | $217.40M | -$154.80M | -$10.30M | -$48.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.34B | $1.31B | $1.19B | $1.26B | $1.21B | $1.16B | $1.04B | $1.11B | $994.20M | $1.00B | $921.00M | $1.03B |
| Gross profit | $864.40M | $830.00M | $750.30M | $792.70M | $731.40M | $688.80M | $589.00M | $655.80M | $593.80M | $626.70M | $561.90M | $656.60M |
| Operating income | $327.20M | $318.30M | $255.30M | $323.00M | $242.50M | $212.60M | $133.70M | $188.90M | $152.00M | $158.00M | $101.10M | $216.90M |
| Net income | $275.10M | $249.10M | $199.50M | $267.30M | $283.80M | $179.80M | $105.40M | $151.70M | $134.60M | $143.50M | $146.40M | $256.30M |
Balance Sheet
As of Dec 2025, total debt of $1.26B exceeded cash and equivalents by $344.80M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.34B | $6.48B | $6.26B | $5.39B | $4.93B | $4.29B | $2.40B | $1.92B | $904.10M | $402.80M |
| Current assets | $4.03B | $4.30B | $4.43B | $3.67B | $3.68B | $3.42B | $1.97B | $1.70B | $744.70M | $280.00M |
| Cash and equivalents | $917.70M | $606.10M | $566.30M | $642.30M | $1.05B | $817.60M | $446.20M | $1.14B | $441.50M | $94.50M |
| Total liabilities | $3.59B | $4.38B | $4.20B | $3.26B | $2.89B | $2.46B | $1.51B | $1.25B | $484.70M | $119.00M |
| Short-term debt | $21.60M | $1.20B | $0 | $772.60M | $0 | $16.50M | $13.60M | $11.70M | $33.40M | $39.10M |
| Long-term debt | $1.24B | $1.24B | $2.43B | $1.20B | $1.98B | $1.67B | $1.06B | $1.01B | $327.60M | $0 |
| Shareholder equity | $2.75B | $2.10B | $2.07B | $2.13B | $2.04B | $1.83B | $882.60M | $663.30M | $419.40M | $283.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.24B | $6.46B | $6.63B | $6.34B | $7.50B | $7.33B | $6.75B | $6.48B | $6.35B | $6.80B | $6.48B | $6.26B |
| Total liabilities | $3.70B | $3.83B | $3.68B | $3.59B | $4.77B | $4.75B | $4.49B | $4.38B | $4.37B | $4.36B | $4.24B | $4.20B |
| Cash and equivalents | $961.40M | $1.10B | $1.12B | $917.70M | $1.84B | $1.16B | $904.90M | $606.10M | $621.20M | $939.20M | $851.20M | $566.30M |
| Shareholder equity | $2.54B | $2.62B | $2.96B | $2.75B | $2.73B | $2.57B | $2.27B | $2.10B | $1.98B | $2.43B | $2.25B | $2.07B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 75.0% of operating cash flow. Share repurchases came to 46.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.44B | $989.50M | $748.50M | $669.50M | $442.50M | $475.60M | $314.50M | $123.20M | $92.00M | $56.20M |
| Capital expenditures | $363.50M | $358.80M | $236.60M | $364.80M | $389.20M | $199.00M | $180.00M | $67.10M | $66.00M | $55.70M |
| Free cash flow | $1.08B | $630.70M | $511.90M | $304.70M | $53.30M | $276.60M | $134.50M | $56.10M | $26.00M | $500.00K |
| Dividends paid | N/A | N/A | $1.23B | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Share repurchases | $500.00M | $750.00M | $688.70M | $557.70M | $0 | $0 | N/A | $100.00M | $0 | $0 |
| Investing cash flow | $536.00M | -$207.50M | -$507.20M | -$521.50M | -$216.10M | -$1.02B | -$1.02B | -$139.80M | -$144.40M | -$55.90M |
| Financing cash flow | -$1.69B | -$734.80M | -$318.60M | -$552.50M | $10.40M | $912.10M | $10.70M | $710.40M | $399.10M | $8.10M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $325.60M | $269.20M | $525.60M | $294.00M | $659.90M | $303.00M | $183.80M | $301.40M | $199.50M | $279.40M | $209.20M | $133.60M |
| Capital expenditures | $52.90M | $84.70M | $76.60M | $101.90M | $80.50M | $94.10M | $87.00M | $124.60M | $111.20M | $66.10M | $56.90M | $52.50M |
| Free cash flow | $272.70M | $184.50M | $449.00M | $192.10M | $579.40M | $208.90M | $96.80M | $176.80M | $88.30M | $213.30M | $152.30M | $81.10M |
Frequently Asked Questions About DXCM
What is DexCom's annual revenue?
DexCom reported revenue of $4.66B for the fiscal year ended Dec 31, 2025.
How fast is DexCom's revenue growing?
Revenue was up 15.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 17.0%.
Is DexCom profitable?
Yes. DexCom reported net income of $836.30M for the fiscal year ended Dec 31, 2025, with a net margin of 17.9%.
How much free cash flow does DXCM generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.44B minus capital expenditures of $363.50M produced free cash flow of $1.08B.
How much debt does DexCom have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.24B, short-term debt of $21.60M and cash and equivalents of $917.70M.
DXCM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors